Start here if you're new
what it is
Fortress buys, develops, and sells drug assets, then tries to cash in on sales, royalties, and ownership stakes.
how it gets paid
Last year Fortress Biotech made $58M in revenue. Commercial product sales was the main engine at $24M, or 41% of sales.
what just happened
Revenue hit $47M, and EPS reached $0.14.
At a glance
C+ balance sheet — struggling to keep the lights on
35/100 earnings predictability — expect surprises
7.2x trailing p/e — the market's not buying it — or you found a deal
-$2.69 fy2024 eps est
$58M fy2024 rev est
xvary composite: 29/100 — weak
What they do
Fortress buys, develops, and sells drug assets, then tries to cash in on sales, royalties, and ownership stakes.
Fortress runs lean. It has 101 employees, not a giant sales army. It also leans on 9 named partners, from AstraZeneca to Dana-Farber, to source assets and spread risk. Your bet is on a small team with a wide partner net.
How they make money
$58M
annual revenue
Commercial product sales
$24M
Royalty revenue
$13M
Equity holding income
$9M
Dividend revenue
$6M
Licensing and other income
$6M
The products that matter
rare disease asset monetization
Cyprium Therapeutics
$205M voucher sale
this subsidiary drove the February 2026 voucher sale worth $205M. that's more than double FBIO's roughly $96M market cap, so one asset just mattered more than the stock market's view of the whole company.
cash event
commercial dermatology business
Journey Medical
$40M segment revenue
this part of the portfolio gives Fortress something closer to recurring revenue, but the recent quarter still showed Emrosi net sales of only $4.9M. useful proof of commercialization, not enough to carry the whole story.
recurring base
product sales and royalties
Commercial portfolio
$18M · 31% of revenue
this is the piece you would want to see grow if Fortress is going to look less like a deal shop and more like an operating business. right now it's the minority of revenue.
31% of revenue
Key numbers
$58M
annual sales
That is the size of the revenue base. It is small enough that one asset can move the whole story.
191.4%
operating loss rate
You lose $1.91 for every $1 of sales. That is a business still paying for its own existence.
$60M
debt load
Debt equals 39% of capital. That leaves less room for mistakes and fewer clean exits.
1.9x
market swing
Your shares move about 1.9 times as much as the market. Small caps do not text back kindly.
Financial health
C+
strength
- balance sheet grade C+ — weak — may struggle to fund operations
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
- long-term debt $60M (39% of capital)
C+ — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for FBIO right now.
source: institutional data · return history unavailable
What just happened
beat estimates
Revenue hit $47M, and EPS reached $0.14.
Sales were up 168% from a year earlier. EPS was up 27% vs. prior year.
$47M
sales
$0.14
profit/share
+168%
sales change
sales
The $47M quarter mattered because it was 168% above last year.
source: company earnings report, 2025
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is mistaking a $205M windfall for a repeatable business model.
med
one-time cash can hide recurring weakness
the voucher sale is real cash, but it is not recurring revenue. annual revenue is only $58M, fy2024 eps is estimated at -$2.69, and the balance sheet carried $60M of long-term debt before the sale.
if that cash gets spent without building a larger recurring revenue base, the post-sale glow fades fast.
med
clinical and deal outcomes drive most of the upside
Fortress does not have a wide, proven commercial engine. you are relying on subsidiaries, approvals, licensing wins, and asset sales to create value across the platform.
when a portfolio company misses, the parent loses both cash and narrative at the same time.
med
volatility can overwhelm fundamentals
a 5 / 100 price stability score and a $1–$5 annual trading range tell you this stock does not move in measured steps. small-cap biotech holding companies rarely do.
even if the underlying business improves, you may still get a chart that behaves like a referendum on the next headline.
med
index exclusion reduces natural buyers
FBIO was dropped from the Russell 3000E Growth Index in June 2025. that matters because passive funds do not buy what they no longer have to own.
for a $96M company, fewer automatic buyers can make liquidity thinner and price moves sharper.
a failed repeat from here would leave you with a weak historical business profile, a small commercial base, and a market asking whether the big win was just one good trade.
source: institutional data · regulatory filings · risk analysis
Pay attention to
capital allocation
what management does with the $205M
cash changed the story. now you need to see whether that money reduces debt, extends runway, or just funds another round of speculative bets.
next report
balance-sheet update after the voucher sale
the next filing should show where the cash landed and how much of the old $60M debt burden still matters.
commercial trend
whether product sales become a bigger share of revenue
product sales and royalties are only $18M today. if that line stays small, Fortress remains dependent on sporadic monetization events.
thesis risk
whether the portfolio produces another real monetization win
one $205M sale proves the model can work once. a second meaningful success is what would start making it look repeatable.
Analyst rankings
earnings predictability
35 / 100
in human-speak, analysts do not expect a clean or steady earnings pattern here.
risk rank
5
risk rank of 5 means the stock looks riskier than about 95% of the market. that's biotech optionality with receipts.
price stability
5 / 100
price stability this low means the market treats FBIO like a binary event list, not a dependable operating company.
source: institutional data
Institutional activity
institutional ownership data for FBIO is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$4
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive